BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients

Genco, Alfredo; Bruni, Teryn; Doldi, S B; Forestieri, Pietro; Marino, Marco; Busetto, Luca; Giardiello, Cristiano; Angrisani, Luigi; Pecchioli, L.; Stornelli, P.; Puglisi, Francesco; Alkilani, M.; Nigri, A; Lorenzo, Nicola Di; Furbetta, Francesco; Cascardo, Antonio; Cipriano, Massimiliano; Lorenzo, Michele; Basso, Nicola

doi:10.1381/0960892055002202

Cited by 330 publications

(268 citation statements)

References 20 publications

(30 reference statements)

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…The majority of these studies have been uncontrolled and/or retrospective (13)(14)(15)(16)(17)(18)(19)(20). Only three studies published to date employed a prospective, randomized, controlled trial design with a long-term follow-up (!1 year) (21-23); two of which included the use of more than one IGB (21,22).…”

Section: Introductionmentioning

confidence: 99%

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Fuller

Pearson

Lau

et al. 2013

Obesity

View full text Add to dashboard Cite

Objective: There are limited controlled data for intragastric balloons (IGB) in obesity treatment. This randomized, controlled study evaluated the efficacy and safety of an IGB in obese individuals with metabolic syndrome (MS). Design and Methods: Sixty-six adults (BMI: 30-40 kg/m 2 ) were randomized to IGB for 6 months, with a 12 month behavioral modification (IGB Group; ''IGBG''), or 12 month behavioral modification alone (Control Group; ''CG''). The primary outcome was percentage change in body weight. Results: Thirty-one subjects (female: 68%; mean age: 43; mean BMI: 36.0) were randomized to IGBG and 35 (66%; 48; 36.7) to CG. At 6 months, there was a significantly greater weight loss in the IGBG: À14.2 vs. À4.8; P < 0.0001. This was associated with a significantly greater reduction in waist circumference, and an improvement in quality of life, with a trend for a larger %MS remission (50% vs. 30%; n.s.). At month 12, the differences in weight loss were enduring: À9.2 vs. À5.2; P ¼ 0.007. Gastrointestinal-related adverse events were common in the IGBG, resolving predominantly within two weeks. The IGB was removed prematurely in three subjects (one for refractory gastrointestinal symptoms). Conclusions: Statistically significant and clinically relevant improvements in weight loss and health outcomes were observed with the IGBG at 6 months versus behavioral modification alone. The differential weight loss was still evident 6 months after IGB removal.

show abstract

Section: Introductionmentioning

confidence: 99%

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Fuller

Pearson

Lau

et al. 2013

Obesity

View full text Add to dashboard Cite

show abstract

“…IGB placement has been developed for this purpose and is used in tandem with advanced technology to provide weight control in morbidly obese patients [11]. IGB placement can deliver weight loss and also reduce comorbidity [12].…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic sleeve gastrectomy versus endoscopical intra-gastric balloon placement: early results of morbidly obese patients

Çaycı

Erdoğdu

2017

Archives of Clinical and Experimental Medicine

View full text Add to dashboard Cite

Atıf yazım şekli:How to cite:Cayci HM, Erdogdu U. Laparoscopic sleeve gastrectomy versus endoscopic intra-gastric balloon placement: Early results of morbidly obese patients. Arch Clin Exp Med. 2017;2(2):35-38.Abstract Aim: Endoscopic intra-gastric balloon (IGB) placement and laparoscopic sleeve gastrectomy (LSG) are widely used treatment modalities for weight loss in patients with morbid obesity. The aim of our study was to evaluate the results of these two methods in patients with morbid obesity. Methods: The data of 119 patients who were treated during the same time period for morbid obesity (Body Mass Index (BMI) ≥40 kg/m2) and completed a 12-month follow-up period were evaluated retrospectively. The study comprised twenty patients who underwent IGB placement and 99 LSG patients. Patients from these two groups were compared according to their demographic data; rate of comorbidity; weight and BMI changes both preoperatively and postoperatively at the 12 months; excess weight loss (EWL); and excess BMI loss (EBL ) nedeniyle aynı dönemde tedavi edilen ve 12 aylık takip dönemini tamamlayan 119 hastanın verileri retrospektif olarak değerlendirildi. Çalışmada İGB uygulanan 20 hasta ve LSG yapılan 99 hasta yer aldı. Hastaların demografik verileri, yandaş hastalık, preoperatif ve postoperatif 12. ayda kilo ve VKİ verileri, verilen fazla kilo ve yüzdeleri, verilen fazla VKİ ve yüzdeleri kaydedilip gruplar karşılaştırıldı. Bulgular: LSG ve İGB grupları arasında preoperatif kilo açısından istatiksel anlamlı farklılık olduğu görüldü (sırasıyla 124,3 ± 17 ve 145,5 ± 24,7; p<0,001). Postoperatif 12. ayda ölçülen kilo değerlendirildiğinde İGB grubunda ortalama 119,2 ±28,5 kg ve LSG grubunda 78,9 ± 12,9 kg saptandı (p<0,001). İGB grubundaki hastaların 12.ay sonunda ortalama 26,3 ±12,8 kg kilo verdiği, LSG grubundaki hastalarında 45,35 ±12,2 kg kilo verdiği görüldü (p<0,001). Postoperatif 12. ayda saptanan verilen fazla kilo yüzdesi İGB grubunda 33,42 ±9,2%, LSG grubunda 67,68 ±14,9% saptandı (p‹0,001). Postoperatif 12.ayda saptanan verilen fazla VKİ yüzdesi açısından İGB grubunda 41 ±17,3%, LSG grubunda 81,48 ±18,8% saptandı (p<0,001). Sonuç: Morbid obes hastalarda endoskopik İGB uygulaması cerrahiye uygun olmayan veya cerrahi tedaviyi tercih etmeyen hastalarda etkin ve güvenli bir tedavi seçeneği olarak tercih edilebilir. Anahtar kelimeler: Morbid obezite, laparoskopik sleeve gastrektomi, intragastik balon

show abstract

“…Despite the use of balloon placement for weight loss since 1985 (4), the clinical efficacy and safety of the method have been evaluated (3)(4)(5). Balloon placement is less invasive when compared to surgery and more effective when compared to medical treatment (3-6); for these reasons, it is a commonly performed procedure.…”

Section: Discussionmentioning

confidence: 99%

A Case of Duodenal Obstruction and Pancreatitis due to Intragastric Balloon

Öztürk¹,

Yavuz²,

Atalay³

2014

Balkan Med J

View full text Add to dashboard Cite

BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients

Abstract: BIB is an effective procedure with satisfactory weight loss and improvement in co-morbidities after 6 months. Previous gastric surgery is a contraindication to BIB placement.

Cited by 330 publications

References 20 publications

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Laparoscopic sleeve gastrectomy versus endoscopical intra-gastric balloon placement: early results of morbidly obese patients

A Case of Duodenal Obstruction and Pancreatitis due to Intragastric Balloon

Contact Info

Product

Resources

About